Serendipitous target-based drug discoveries

János Fischer, David P. Rotella

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Drug discoveries of the past decades are characterized by an increasing knowledge of molecular biology. In the case of target-based drug discovery, the starting point of the research is a known molecular biological target. There are several therapeutic fields, such as hypertension, obstructive airway diseases, diabetes, and chronic myeloid leukemia whose treatment essentially improved by target-based drug discoveries. A short overview of dapagliflozin, trastuzumab emtansine, sofosbuvir, tofacitinib, and apremilast affords recent examples of target-based drug discoveries. In some special cases, however, the initial drug target only initiates the drug discovery to find a lead molecule; however, the final drug product has a different mechanism of action. Examples of such serendipitous drug discoveries are overviewed by examples of drospirenone, escitalopram, ezetimibe, lamotrigine, and omeprazole.

Original languageEnglish
Title of host publicationSuccessful Drug Discovery
Publisherwiley
Pages3-18
Number of pages16
ISBN (Electronic)9783527336852
ISBN (Print)9783527678433
DOIs
StatePublished - 30 Jan 2015

Keywords

  • Apremilast
  • Dapagliflozin
  • Drospirenone
  • Escitalopram
  • Ezetimibe
  • Lamotrigine
  • Omeprazole
  • Serendipitous target-based drug discoveries
  • Sofosbuvir
  • Target-based drug discovery
  • Tofacitinib
  • Trastuzumab emtansine

Fingerprint Dive into the research topics of 'Serendipitous target-based drug discoveries'. Together they form a unique fingerprint.

  • Cite this

    Fischer, J., & Rotella, D. P. (2015). Serendipitous target-based drug discoveries. In Successful Drug Discovery (pp. 3-18). wiley. https://doi.org/10.1002/9783527678433.ch1